India, Sept. 9 -- HDFC Asset Management Company Limited (HDFC AMC), the investment manager of HDFC Mutual Fund (HDFC MF) and one of India's leading mutual fund houses, referred to the performance of HDFC Pharma and Healthcare Fund, which delivered a CAGR of 30.19% since inception and a return of 19.01% over one year, as of July 31, 2026. The fund was launched on October 4, 2023, and seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of pharma and healthcare companies.

The fund is diversified across pharmaceuticals, hospitals, healthcare service providers, biotechnology, and medical equipment and supplies. India's pharmaceutical and healthcare sector presents a structural g...